NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 33.9% and is now trading at $622.07. View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 13 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $6.13 by $0.47. The biopharmaceutical company earned $1.83 billion during the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. Regeneron Pharmaceuticals's revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.45 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its Board of Directors has approved a share buyback program on Tuesday, November 5th 2019, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued.

27 brokerages have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $734.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $557.70 in the next year. This suggests that the stock has a possible downside of 10.3%. View analysts' price targets for Regeneron Pharmaceuticals.

Press coverage about REGN stock has been trending very negative on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 1,990,000 shares, an increase of 11.8% from the May 31st total of 1,780,000 shares. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.9% of the company's stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $622.07.

Regeneron Pharmaceuticals has a market capitalization of $68.44 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]